Seviteronel
Seviteronel is an experimental cancer medication which is under development by Viamet Pharmaceuticals and Innocrin Pharmaceuticals for the treatment of prostate cancer and breast cancer. It is a nonsteroidal CYP17A1 inhibitor and works by inhibiting the production of androgens and estrogens in the body. As of July 2017, seviteronel is in phase II clinical trials for both prostate cancer and breast cancer. In January 2016, it was designated fast-track status by the United States Food and Drug Administration for prostate cancer. In April 2017, seviteronel received fast-track designation for breast cancer as well.Pharmacology
Pharmacodynamics
Seviteronel is a nonsteroidal antiandrogen, acting specifically as an androgen synthesis inhibitor via inhibition of the enzyme CYP17A1, for the treatment of castration-resistant prostate cancer. It has approximately 10-fold selectivity for the inhibition of 17,20-lyase over 17α-hydroxylase, which results in less interference with corticosteroid production relative to the approved CYP17A1 inhibitor abiraterone acetate and hence may be administerable without a concomitant exogenous glucocorticoid. Seviteronel is 58-fold more selective for inhibition of 17,20-lyase than abiraterone, which has values for inhibition of 17,20-lyase and 17α-hydroxylase of 15 nM and 2.5 nM, respectively. In addition, in in vitro models, seviteronel appears to possess greater efficacy as an antiandrogen relative to abiraterone. Similarly to abiraterone acetate, seviteronel has also been found to act to some extent as an antagonist of the androgen receptor.Society and culture
Seviteronel is the generic name of the drug and its.
